Antigenic determinants of asthma-associated allergens for design of immunotherapy

用于免疫治疗设计的哮喘相关过敏原的抗原决定簇

基本信息

  • 批准号:
    10630249
  • 负责人:
  • 金额:
    $ 53.79万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2009
  • 资助国家:
    美国
  • 起止时间:
    2009-08-25 至 2025-05-31
  • 项目状态:
    未结题

项目摘要

TITLE: Antigenic determinants of asthma-associated allergens for design of immunotherapy PROJECT SUMMARY/ABSTRACT House dust mite allergy is an important health problem worldwide, affecting up to 85% of asthmatic children, and a risk factor for emergency room admission with asthma. Group 1 and 2 mite allergens account for more than 50% of total house dust mite specific IgE reactivity in mite allergic patients. Recently, Der p 23 has also been identified as a major mite allergen, but its contribution to the total house dust mite specific IgE is small. Group 1 allergens are cysteine proteases that contribute to lung inflammation in asthma, whereas group 2 allergens are lipopolysaccharide binding proteins. Der p 2 has been reported to mimic a human structural- homolog that activates the innate immune system through toll like receptors. Despite these important molecular differences between proteolytic group 1 and non-proteolytic group 2, a high IgE prevalence of 83% to allergens from both groups has been observed in mite allergic patients in the U.S. However, the IgE repertoire and antigenic determinants associated with these two major allergens are not known. The main goal of this project is to investigate the antigenic structure of both groups of mite allergens for the design of immunotherapy. Allergen-specific IgE monoclonal antibodies (mAb) will be produced for the first time with the correct pairing of the heavy and light chains as they occur in vivo, using hybridomas obtained from the fusion of B cells from allergic donors with a myeloma partner that confers immortality. Allergens will be co-crystallized with recombinant IgE antibody constructs. The key amino acids involved in IgE antibody binding will be identified and modified. The specific aims are: 1) Isolation of IgE mAb specific for asthma-associated allergens by hybridoma technology; 2) mapping of antigenic determinants on groups 1 and 2 dust mite allergens by X-ray crystallography and analysis of IgE antibody binding epitopes; and 3) site-directed mutagenesis of IgE antibody epitopes for expression of hypoallergenic mutants with T cell reactivity as candidates for immunotherapy. An analysis of the association between mite allergen-specific IgE antibodies from the human repertoire and the epitopes recognized by these IgE antibodies will be performed with the information obtained in the first two aims. Aim #2 will generate experimental data sets of three-dimensional structures of B-cell epitopes, which are currently missing in databases used for developing tools for B cell epitope prediction. Most importantly, this project will define IgE antibody responses to mite allergens and will provide the structural basis for rational design of hypoallergens. In Aim #3, IgE antibody binding to the epitope mutants will be analyzed by immunoassays and cell mediator release assays, and T cell reactivity will be evaluated. Mutants will be compared and hypoallergenic forms will be selected for the design of vaccines for immunotherapy of mite allergy.
题目:哮喘相关过敏原的抗原决定因素用于免疫治疗设计

项目成果

期刊论文数量(52)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Serological, genomic and structural analyses of the major mite allergen Der p 23.
主要螨过敏原p23的血清学,基因组和结构分析。
100 Years later: Celebrating the contributions of x-ray crystallography to allergy and clinical immunology.
100 年后:庆祝 X 射线晶体学对过敏和临床免疫学的贡献。
  • DOI:
    10.1016/j.jaci.2015.05.016
  • 发表时间:
    2015
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Pomés,Anna;Chruszcz,Maksymilian;Gustchina,Alla;Minor,Wladek;Mueller,GeoffreyA;Pedersen,LarsC;Wlodawer,Alexander;Chapman,MartinD
  • 通讯作者:
    Chapman,MartinD
Biological activity of human IgE monoclonal antibodies targeting Der p 2, Fel d 1, Ara h 2 in basophil mediator release assays.
  • DOI:
    10.3389/fimmu.2023.1155613
  • 发表时间:
    2023
  • 期刊:
  • 影响因子:
    7.3
  • 作者:
    Pena-Castellanos, Glorismer;Smith, Bryan R. E.;Pomes, Anna;Smith, Scott A.;Stigler, Maria A.;Widauer, Hannah L.;Versteeg, Serge A.;van Ree, Ronald;Chapman, Martin D.;Aglas, Lorenz
  • 通讯作者:
    Aglas, Lorenz
A robust method for the estimation and visualization of IgE cross-reactivity likelihood between allergens belonging to the same protein family.
  • DOI:
    10.1371/journal.pone.0208276
  • 发表时间:
    2018
  • 期刊:
  • 影响因子:
    3.7
  • 作者:
    Chruszcz M;Kapingidza AB;Dolamore C;Kowal K
  • 通讯作者:
    Kowal K
Characterization of an anti-Bla g 1 scFv: epitope mapping and cross-reactivity.
  • DOI:
    10.1016/j.molimm.2014.02.003
  • 发表时间:
    2014-06
  • 期刊:
  • 影响因子:
    3.6
  • 作者:
    Mueller GA;Ankney JA;Glesner J;Khurana T;Edwards LL;Pedersen LC;Perera L;Slater JE;Pomés A;London RE
  • 通讯作者:
    London RE
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

MARTIN D. CHAPMAN其他文献

MARTIN D. CHAPMAN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('MARTIN D. CHAPMAN', 18)}}的其他基金

High Throughput Immunoassay for Flagellin
鞭毛蛋白的高通量免疫分析
  • 批准号:
    8516169
  • 财政年份:
    2013
  • 资助金额:
    $ 53.79万
  • 项目类别:
Antigenic determinants of asthma-associated allergens for design of immunotherapy
用于免疫治疗设计的哮喘相关过敏原的抗原决定簇
  • 批准号:
    8086141
  • 财政年份:
    2010
  • 资助金额:
    $ 53.79万
  • 项目类别:
TAS::75 0862::TAS
塔斯马尼亚州::75 0862::塔斯马尼亚州
  • 批准号:
    8164000
  • 财政年份:
    2010
  • 资助金额:
    $ 53.79万
  • 项目类别:
Antigenic determinants of asthma-associated allergens for design of immunotherapy
用于免疫治疗设计的哮喘相关过敏原的抗原决定簇
  • 批准号:
    10413107
  • 财政年份:
    2009
  • 资助金额:
    $ 53.79万
  • 项目类别:
Antigenic determinants of asthma-associated allergens for design of immunotherapy
用于免疫治疗设计的哮喘相关过敏原的抗原决定簇
  • 批准号:
    8132855
  • 财政年份:
    2009
  • 资助金额:
    $ 53.79万
  • 项目类别:
Antigenic determinants of asthma-associated allergens for design of immunotherapy.
用于免疫治疗设计的哮喘相关过敏原的抗原决定因素。
  • 批准号:
    8960085
  • 财政年份:
    2009
  • 资助金额:
    $ 53.79万
  • 项目类别:
Antigenic determinants of asthma-associated allergens for design of immunotherapy
用于免疫治疗设计的哮喘相关过敏原的抗原决定簇
  • 批准号:
    10196971
  • 财政年份:
    2009
  • 资助金额:
    $ 53.79万
  • 项目类别:
Antigenic determinants of asthma-associated allergens for design of immunotherapy.
用于免疫治疗设计的哮喘相关过敏原的抗原决定因素。
  • 批准号:
    9067975
  • 财政年份:
    2009
  • 资助金额:
    $ 53.79万
  • 项目类别:
Antigenic determinants of asthma-associated allergens for design of immunotherapy
用于免疫治疗设计的哮喘相关过敏原的抗原决定簇
  • 批准号:
    7726352
  • 财政年份:
    2009
  • 资助金额:
    $ 53.79万
  • 项目类别:
Antigenic determinants of asthma-associated allergens for design of immunotherapy.
用于免疫治疗设计的哮喘相关过敏原的抗原决定因素。
  • 批准号:
    9540201
  • 财政年份:
    2009
  • 资助金额:
    $ 53.79万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了